Responses
Clinical/translational cancer immunotherapy
Original research
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial
Compose a Response to This Article
Other responses
No responses have been published for this article.